Wanberg LJ, Schultz B, Goyal A. Treatment of Subcorneal Pustular Dermatosis without Dapsone: A Case Report and Review of the Literature.
Case Rep Dermatol Med 2024;
2024:8140483. [PMID:
38596599 PMCID:
PMC11003796 DOI:
10.1155/2024/8140483]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 03/06/2024] [Accepted: 03/14/2024] [Indexed: 04/11/2024] Open
Abstract
Subcorneal pustular dermatosis (SPD) is a rare neutrophilic dermatosis characterized by pustules on the trunk and intertriginous areas. While oral dapsone is the first-line treatment for SPD, alternative options are necessary for patients with glucose-6-phosphate dehydrogenase deficiency, drug hypersensitivity reactions, or refractory disease. To date, no consensus exists regarding next-best agents for SPD. In this report, we present a patient with significant SPD who developed dapsone hypersensitivity syndrome and then was successfully treated with colchicine and adalimumab. We propose that colchicine should be considered as a second-line treatment for SPD and present a therapeutic algorithm for clinicians to utilize when patients are not candidates for dapsone, have side effects requiring drug discontinuation, or have refractory disease.
Collapse